Showing results (651-660 of 678) with videos related to

Sort By:
Pageof 68
The Lancet. Oncology|November 18, 2021
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialJonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.
American Journal of Otolaryngology|April 15, 2021
N95 respirator reuse, decontamination methods, and microbial burden: A randomized controlled trialZi Yang Jiang, Zhen Huang, Isaac Schmale, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 30, 2016
Longitudinal investigation of nasopharyngeal methicillin-resistant Staphylococcus aureus colonization in early infancy: The PATCH birth cohort studyM-H Tsai, C-Y Chiu, H-J Shih, et al.
Lancet (London, England)|December 26, 2015
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyJames C Yao, Nicola Fazio, Simron Singh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 27, 2013
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancerJ A Ajani, L Xiao, J A Roth, et al.
International Forum of Allergy & Rhinology|April 12, 2023
Determinants of physician assessment of chronic rhinosinusitis disease control using EPOS 2020 criteria and the importance of incorporating patient perspectives of disease controlAhmad R Sedaghat, David S Caradonna, Rakesh K Chandra, et al.
Pancreas|June 14, 2017
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine TumorsJonathan R Strosberg, Thorvardur R Halfdanarson, Andrew M Bellizzi, et al.
Cancer Biomarkers : Section a of Disease Markers|September 13, 2024
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with NivolumabYehia I Mohamed, Sunyoung S Lee, Tarik Demir, et al.
Oncology|July 7, 2017
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United StatesHumaid O Al-Shamsi, Reham Abdel-Wahab, Manal M Hassan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2022
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)Pamela L Kunz, Noah T Graham, Paul J Catalano, et al.
Pageof 68